OverviewChartNewsTraderScreen

Obseva SA/  CH1260041939  /

Nasdaq Other OTC
24/04/2023  21:51:22 Chg. - Volume Bid23/03/2023 Ask23/03/2023 High Low
0.0840USD - 127,403
Turnover: 11,030.1059		 0.0824Bid Size: 900 0.0847Ask Size: 5,200 0.0980 0.0800
GlobeNewswire 03/04 ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated...
GlobeNewswire 19/03 ObsEva Announces Update on Board of Directors
GlobeNewswire 08/03 XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming ...
GlobeNewswire 28/02 ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establi...
GlobeNewswire 31/01 Geneva Court Grants Temporary Moratorium to ObsEva
GlobeNewswire 30/11/2023 ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
GlobeNewswire 07/11/2023 XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive S...
GlobeNewswire 27/10/2023 Organon Returns Ebopiprant to XOMA
GlobeNewswire 27/09/2023 ObsEva Files half Year 2023 Financial Statements
GlobeNewswire 22/03/2022 ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and L...
GlobeNewswire 22/03/2022 ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and L...
GlobeNewswire 10/03/2022 ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
GlobeNewswire 10/02/2022 ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
GlobeNewswire 04/02/2022 ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist...
GlobeNewswire 01/02/2022 ObsEva Appoints Katja Buhrer as Chief Strategy Officer
GlobeNewswire 28/01/2022 ObsEva Announces Corporate Updates
GlobeNewswire 06/01/2022 ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3...
GlobeNewswire 05/01/2022 Aspira Women’s Health Announces Fourth Quarter Operational Metrics and Provides Updates on Its OvaWa...
GlobeNewswire 03/01/2022 ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference
GlobeNewswire 17/12/2021 ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of...
GlobeNewswire 13/12/2021 ObsEva Appoints Will Brown as Chief Financial Officer
GlobeNewswire 11/12/2021 Annual Changes to the Nasdaq Biotechnology Index
GlobeNewswire 10/12/2021 ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congres...
GlobeNewswire 02/12/2021 ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at S...
GlobeNewswire 29/11/2021 Rapid7 Appoints Tim Adams as Chief Financial Officer